May 9, 2012
Japan Tobacco (JT) announced on May 7 that F. Hoffmann-La Roche of Switzerland has decided to discontinue all development of the dyslipidemia treatment JTT-705 (dalcetrapib), which was discovered by JT and licensed to Roche. In 2004, JT concluded a license...read more